Furthermore, three intratumoral infiltrating immune markers (CD15, CD206 and CD117) and one SMAD4 mutation were found to be associated with recurrence and survival in patients after surgery for PDAC [17] and G protein alpha-driven oncogenic mechanisms, Siks revealed unanticipated metabolic heterogeneity among KRAS-mutant pancreatic neoplasms and evidenced to be a potent tumor suppressor [18]. Here, KRAS is linked to pancreatic neoplasm.